Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

© 2015, Annals of Neurosciences. All Rights Reserved. Knowing and managing the cross cultural and multi-disciplinary benefits and limitations of comparative effectiveness research (CER) will be the key component in building a strong foundation for the proof of concept in precision medicine.Unprecedented funding for CER is now available but this often favors national applicants even though the research is completed in other nations. There is a spill-over effect into low and middle income countries (LMIC), where device manufacturers, pharmaceutical companies, and regenerative technology corporations are investing in for the benefits of reduced site costs, supplies, and faster turn around times.Corporations ostensibly enjoy the opportunity to work in relative obscurity, thus protecting the proprietary aspects of development in a more lenient regulatory milieu with reduced ethical scrutiny.

Original publication




Journal article


Annals of neurosciences

Publication Date





127 - 129